Emerging data suggest this peptide, a dual agonist targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , may provide a significant advancement for body loss . Initial patient tests have indicated impressive reductions in body mass , possibly exceeding existing obesity medications . Despite this, additional assessment